Gerald Brunk Acquires 31,000 Shares of enGene Therapeutics

On June 16, 2026, Gerald Brunk purchased 31,000 shares of enGene Therapeutics Inc. (NasdaqCM:ENGN). This insider transaction was not part of a pre-planned trading program.

enGene Therapeutics Stock Snapshot

Shares of enGene Therapeutics traded near $1.75. The company's market cap stands at approximately $117.2 million. enGene is not currently profitable, so it has no meaningful P/E ratio. The stock has seen a 52-week low of $1.40 and a high of $12.25, with a 50-day moving average of $4.33 and a 200-day moving average of $7.13. The firm maintains a strong liquidity position with a current ratio of 12.57 and a quick ratio of 12.07, although it has a debt-to-equity ratio of 13.07.

About enGene Therapeutics

enGene Therapeutics Inc. is a clinical-stage biotechnology company based in Montreal, Canada. The company focuses on developing genetic medicines aimed at treating bladder cancer. Its lead product candidate, detalimogene voraplasmid, is a monotherapy for non-muscle invasive bladder cancer. The company also has a pipeline project called LEGEND, which is in Phase 2. enGene Therapeutics is led by CEO Ronald H. W. Cooper and employs 81 people.

Bottom Line

Gerald Brunk's recent purchase of enGene Therapeutics shares highlights ongoing insider interest in the company. Investors often watch insider transactions for insights into company prospects, though it's important to remember that such trades don't always predict stock performance. enGene Therapeutics continues to focus on its genetic medicine pipeline, offering potential growth in the healthcare sector.